Investing.com - Ascendis Pharma AS reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Ascendis Pharma AS announced earnings per share of €-2.31 on revenue of €2.76M. Analysts polled by Investing.com anticipated EPS of €-1.58 on revenue of €1.4M.
Ascendis Pharma AS shares are up 15.01% from the beginning of the year and are trading at €160.00 , down-from-52-week-high.They are under-performing the Nasdaq which is up 31.36% from the start of the year.
Ascendis Pharma AS follows other major Healthcare sector earnings this month
Ascendis Pharma AS's report follows an earnings beat by J&J on Tuesday, October 13, 2020, who reported EPS of €2.2 on revenue of €21.08B, compared to forecasts EPS of €1.98 on revenue of €20.2B.
Pfizer had beat expectations on Tuesday, October 27, 2020 with third quarter EPS of €0.72 on revenue of €12.13B, compared to forecast for EPS of €0.71 on revenue of €12.31B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar